Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections

Scope and hope for the future

K. Mazumdar, K. Asok Kumar, Noton Dutta

Research output: Contribution to journalShort survey

Abstract

The appearance of multiresistant bacterial strains coupled with the globally ongoing problem of infectious diseases point to the imperative need for novel and affordable antimicrobial drugs. The antibacterial potential of cardiovascular non-antibiotics such as amlodipine (AML), dobutamine, lacidipine, nifedipine and oxyfedrine has been reported previously. Of these drugs, AML proved to have the most significant antibacterial activity against Gram-positive and Gram-negative bacteria. Time-kill curve studies indicate that this Ca2+ channel blocker exhibits bactericidal activity against Listeria monocytogenes and Staphylococcus aureus. AML could protect against murine listeriosis and salmonellosis at doses ranging within its maximum recommended human or non-toxic ex vivo dose. AML acts as a 'helper compound' in synergistic combination with streptomycin against several Gram-positive and Gram-negative bacterial strains in vitro as well as in the murine salmonellosis model in vivo. The present review focuses on the possible use of cardiovascular non-antibiotics such as AML as auxiliary compound targets for synergistic combinations in infections and hypertension conditions, rationalised on the basis of the activities of the compounds.

Original languageEnglish (US)
Pages (from-to)295-302
Number of pages8
JournalInternational Journal of Antimicrobial Agents
Volume36
Issue number4
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Amlodipine
Infection
Salmonella Infections
Oxyfedrine
Listeriosis
Dobutamine
Listeria monocytogenes
Streptomycin
Nifedipine
Gram-Negative Bacteria
Pharmaceutical Preparations
Communicable Diseases
Staphylococcus aureus
Hypertension

Keywords

  • Amlodipine
  • Cardiovascular drugs
  • Helper compound
  • Microbial infections
  • Non-antibiotic

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

@article{e9d144f88ee243eab590a9e418fe4965,
title = "Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: Scope and hope for the future",
abstract = "The appearance of multiresistant bacterial strains coupled with the globally ongoing problem of infectious diseases point to the imperative need for novel and affordable antimicrobial drugs. The antibacterial potential of cardiovascular non-antibiotics such as amlodipine (AML), dobutamine, lacidipine, nifedipine and oxyfedrine has been reported previously. Of these drugs, AML proved to have the most significant antibacterial activity against Gram-positive and Gram-negative bacteria. Time-kill curve studies indicate that this Ca2+ channel blocker exhibits bactericidal activity against Listeria monocytogenes and Staphylococcus aureus. AML could protect against murine listeriosis and salmonellosis at doses ranging within its maximum recommended human or non-toxic ex vivo dose. AML acts as a 'helper compound' in synergistic combination with streptomycin against several Gram-positive and Gram-negative bacterial strains in vitro as well as in the murine salmonellosis model in vivo. The present review focuses on the possible use of cardiovascular non-antibiotics such as AML as auxiliary compound targets for synergistic combinations in infections and hypertension conditions, rationalised on the basis of the activities of the compounds.",
keywords = "Amlodipine, Cardiovascular drugs, Helper compound, Microbial infections, Non-antibiotic",
author = "K. Mazumdar and {Asok Kumar}, K. and Noton Dutta",
year = "2010",
month = "10",
doi = "10.1016/j.ijantimicag.2010.05.003",
language = "English (US)",
volume = "36",
pages = "295--302",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections

T2 - Scope and hope for the future

AU - Mazumdar, K.

AU - Asok Kumar, K.

AU - Dutta, Noton

PY - 2010/10

Y1 - 2010/10

N2 - The appearance of multiresistant bacterial strains coupled with the globally ongoing problem of infectious diseases point to the imperative need for novel and affordable antimicrobial drugs. The antibacterial potential of cardiovascular non-antibiotics such as amlodipine (AML), dobutamine, lacidipine, nifedipine and oxyfedrine has been reported previously. Of these drugs, AML proved to have the most significant antibacterial activity against Gram-positive and Gram-negative bacteria. Time-kill curve studies indicate that this Ca2+ channel blocker exhibits bactericidal activity against Listeria monocytogenes and Staphylococcus aureus. AML could protect against murine listeriosis and salmonellosis at doses ranging within its maximum recommended human or non-toxic ex vivo dose. AML acts as a 'helper compound' in synergistic combination with streptomycin against several Gram-positive and Gram-negative bacterial strains in vitro as well as in the murine salmonellosis model in vivo. The present review focuses on the possible use of cardiovascular non-antibiotics such as AML as auxiliary compound targets for synergistic combinations in infections and hypertension conditions, rationalised on the basis of the activities of the compounds.

AB - The appearance of multiresistant bacterial strains coupled with the globally ongoing problem of infectious diseases point to the imperative need for novel and affordable antimicrobial drugs. The antibacterial potential of cardiovascular non-antibiotics such as amlodipine (AML), dobutamine, lacidipine, nifedipine and oxyfedrine has been reported previously. Of these drugs, AML proved to have the most significant antibacterial activity against Gram-positive and Gram-negative bacteria. Time-kill curve studies indicate that this Ca2+ channel blocker exhibits bactericidal activity against Listeria monocytogenes and Staphylococcus aureus. AML could protect against murine listeriosis and salmonellosis at doses ranging within its maximum recommended human or non-toxic ex vivo dose. AML acts as a 'helper compound' in synergistic combination with streptomycin against several Gram-positive and Gram-negative bacterial strains in vitro as well as in the murine salmonellosis model in vivo. The present review focuses on the possible use of cardiovascular non-antibiotics such as AML as auxiliary compound targets for synergistic combinations in infections and hypertension conditions, rationalised on the basis of the activities of the compounds.

KW - Amlodipine

KW - Cardiovascular drugs

KW - Helper compound

KW - Microbial infections

KW - Non-antibiotic

UR - http://www.scopus.com/inward/record.url?scp=77955923752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955923752&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2010.05.003

DO - 10.1016/j.ijantimicag.2010.05.003

M3 - Short survey

VL - 36

SP - 295

EP - 302

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 4

ER -